{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:58:46Z","timestamp":1758049126852,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","award":["2021SF-302","2021ZDLSF02-17"],"award-info":[{"award-number":["2021SF-302","2021ZDLSF02-17"]}],"id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bbrc.2022.09.032","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T02:44:31Z","timestamp":1662864271000},"page":"152-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy"],"prefix":"10.1016","volume":"629","author":[{"given":"Hui","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-5906","authenticated-orcid":false,"given":"Mengyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jincheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4621-9337","authenticated-orcid":false,"given":"Fan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.09.032_bib1","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41375-018-0314-7","article-title":"Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality","volume":"33","author":"Reedijk","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2022.09.032_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17512433.2019.1573668","article-title":"Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review","volume":"12","author":"Meg\u00edas-Vericat","year":"2019","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2022.09.032_bib4","first-page":"62","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission, Blood","volume":"127","author":"Cornelissen","year":"2016","journal-title":"J.\u00a0Am Soc. Hematol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib6","doi-asserted-by":"crossref","first-page":"10041","DOI":"10.1007\/s13277-016-5067-1","article-title":"Significance of oncogenes and tumor suppressor genes in AML prognosis","volume":"37","author":"Kavianpour","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib7","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.09.032_bib8","first-page":"722","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia, Blood","volume":"130","author":"Stein","year":"2017","journal-title":"J.\u00a0Am Soc. Hematol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib9","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.09.032_bib10","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2022.09.032_bib11","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/bloodadvances.2017009829","article-title":"The role of targeted therapy in the management of patients with AML","volume":"1","author":"Perl","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2022.09.032_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell."},{"key":"10.1016\/j.bbrc.2022.09.032_bib13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody\u2013drug conjugates: current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2022.09.032_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2021.1875814","article-title":"A\u00a0review of FDA-approved acute myeloid leukemia therapies beyond \u20187+ 3","volume":"14","author":"Bazinet","year":"2021","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib15","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","article-title":"FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid LeukemiaFDA approval summary: gemtuzumab ozogamicin","volume":"24","author":"Jen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.09.032_bib16","first-page":"414","article-title":"FDA approves ADC Therapeutics' loncastuximab tesirine, ushering in a new cytotoxic payload","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2022.09.032_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/13543784.2020.1800638","article-title":"Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma","volume":"29","author":"Bourbon","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2022.09.032_bib18","series-title":"FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma","first-page":"OF1","author":"Baines","year":"2022"},{"key":"10.1016\/j.bbrc.2022.09.032_bib19","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-Cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2022.09.032_bib21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg\u00ae) treatment in acute myeloid leukemia patients","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2022.09.032_bib22","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"year":"2010","series-title":"Pfizer to Withdraw a Cancer Drug Mylotarg","author":"Dooren","key":"10.1016\/j.bbrc.2022.09.032_bib23"},{"key":"10.1016\/j.bbrc.2022.09.032_bib24","first-page":"2373","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia, Blood","volume":"130","author":"Appelbaum","year":"2017","journal-title":"J.\u00a0Am Soc. Hematol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev."},{"key":"10.1016\/j.bbrc.2022.09.032_bib26","first-page":"3705","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML, Blood","volume":"119","author":"Pollard","year":"2012","journal-title":"J.\u00a0Am Soc. Hematol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib27","first-page":"1187","article-title":"Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells","volume":"23","author":"Ikezoe","year":"2003","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.biocel.2011.01.020","article-title":"An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics","volume":"43","author":"Li","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbrc.2022.09.032_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2184.2012.00849.x","article-title":"Oridonin: targeting programmed cell death pathways as an anti-tumour agent","volume":"45","author":"Liu","year":"2012","journal-title":"Cell Prolif"},{"key":"10.1016\/j.bbrc.2022.09.032_bib30","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/CAD.0000000000000154","article-title":"Oridonin inhibits mTOR signaling and the growth of lung cancer tumors","volume":"25","author":"Wang","year":"2014","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.bbrc.2022.09.032_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104313","article-title":"Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects","volume":"146","author":"Li","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2022.09.032_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2014.12.086","article-title":"Oridonin induces apoptosis in uveal melanoma cells by upregulation of Bim and downregulation of fatty acid synthase","volume":"457","author":"Gu","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2022.09.032_bib33","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-06-032250","article-title":"Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t (8; 21) leukemia in\u00a0vitro and in\u00a0vivo","volume":"109","author":"Zhou","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2022.09.032_bib34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3892\/or.2013.2888","article-title":"Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53-and caspase-dependent induction of p38 MAPK","volume":"31","author":"Bu","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2022.09.032_bib35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4161\/auto.5.3.7896","article-title":"Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells","volume":"5","author":"Cheng","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.bbrc.2022.09.032_bib36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/molecules25020332","article-title":"Solubility and bioavailability enhancement of oridonin: a review","volume":"25","author":"Zhang","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2022.09.032_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biomaterials.2018.03.025","article-title":"Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy","volume":"167","author":"Niu","year":"2018","journal-title":"Biomaterials"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22012827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22012827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:23:00Z","timestamp":1757766180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22012827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"alternative-id":["S0006291X22012827"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.09.032","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}